RE: FLT316 May 2025 22:45
Hi, HBD & Krone
And for me there lies the problem JR &TM should be 110% focussed on getting both Toxicity Studies and Clinical report into the zone of progression first as it is our most immediate valued asset, SP brings back SRA737, a bonus if it can be flipped and bring in a short/mid term cash cow as not on the radar 6 months ago, 1802 transitional and CNS wait your turn after above, at this stage FLT3 not a consideration, get your marker on the table for the market to see our value, not loads of maybe’s - our sp needs to get back to true related value of our assets and from there we and the “Market” can speculate in our own ways of potential values, raises, JV’s, M&A’s etc etc
TM interjected at the IMC that “Yes, SRA737 is in the shop window”, be good to know where he shops as per the song “ain’t seen nothing yet”!
The above is not rocket science, just simple business acumen on the reality of what we have, how we should be progressing to a better potential in due course, but, would help to get the Toxicity Studies started incase anybody up in sleepy Pampisford has forgotten what the business model is (I live 30 mins away, so know how sleepy it is up there).
Of course, above is only my opinion and happy for others to opinionate and correct me!
GLA